<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107388</url>
  </required_header>
  <id_info>
    <org_study_id>2021/609</org_study_id>
    <nct_id>NCT05107388</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer</brief_title>
  <acronym>AAREN</acronym>
  <official_title>AAREN: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the glycemic profile of postmenopausal women treated&#xD;
      with alpelisib plus fulvestrant using a continuous blood sugar monitoring device (FreeStyle&#xD;
      Libre Pro) over 14 days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AAREN is a monocentric prospective study monitoring glycemic profile in patients treated with&#xD;
      alpelisib plus fulvestrant. Patients will wear a noninvasive glucose monitoring sensor, the&#xD;
      Freestyle Libre Pro for a 14 day period. Forty patients will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of hyperglycemia</measure>
    <time_frame>Day 14</time_frame>
    <description>In percentage, measured before breakfast and diner (fasting blood glucose).&#xD;
Hyperglycemia defined as follows:&#xD;
if diabetes de novo:&#xD;
capillar or interstitial fasting blood glucose ≥ 1,50 g/L,&#xD;
OR postprandial interstitial glucose ≥ 2 g/L&#xD;
OR glucose monitoring indicator ≥ 6,5%&#xD;
if worsening pre-existing diabetes:&#xD;
increased capillar or interstitial fasting blood glucose ≥ 0,50 g/L compared to average fasting blood glucose at J-3, J-2 and J-1&#xD;
AND postprandial interstitial glucose ≥ + 1,00 g/L compared to average fasting blood glucose at J-3, J-2 et J-1 OR average blood glucose ≥ +0,50 g/L</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Continuous interstitial glucose measurements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Variations of interstitial glucose are measured during 14 days with FreeStyle Libre Pro</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Libre Pro</intervention_name>
    <description>Measurements of interstitial glucose variations with FreeStyle Libre Pro</description>
    <arm_group_label>Continuous interstitial glucose measurements</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women suffering breast cancer and eligible to treatment with Alpelisib&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Menopausal women (for at least 24 months)&#xD;
&#xD;
          4. Informed Consent Form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Men&#xD;
&#xD;
          2. Pregnant ou child-bearing potential women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie BOROT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatimata SARR SALL, PhD</last_name>
    <phone>033381219449</phone>
    <email>fatimata.sarr@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fatimata SARR SALL, PhD</last_name>
      <email>fatimata.sarr@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer, Alpelisib, hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

